ACTH (7-39) human FR-W-GKPVGKKRRPVKVYPNGAEDESAEAFPLEF-acid
Competitive antagonist of ACTHR/MC2R.
Catalogue number crb1000333 Molecular Weight 3804 Sequence (one letter code) FR-W-GKPVGKKRRPVKVYPNGAEDESAEAFPLEF-acid Sequence (three letter code)
Purity >95% References
Ghaddhab et al (2017) From Bioinactive ACTH to ACTH Antagonist: The Clinical Perspective. Front. Endocrinol. (Lausanne) 8 PMID: 28228747
Iwayama et al (2018) Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review. BMC Endocr. Disord. 18(1) PMID: 29587720
Kapas et al (1996) Agonist and receptor binding properties of adrenocorticotropin peptides using the cloned mouse adrenocorticotropin receptor expressed in a stably transfected HeLa cell line. Endocrinology 137(8) 329 PMID: 8754753
Manufactured in: United Kingdom
C- terminal fragment of adrenocorticotropic hormone (ACTH) also known as corticotropin, and competitive antagonist of ACTH receptor (ACTHR), also known as melanocortin type 2 receptor (MC2R).
ACTH is a member of the melanocortins peptide family, this tropic hormone is produced and secreted by the anterior pituitary gland. ACTH is an important component of the hypothalamic-pituitary-adrenal (HPA) axis and is often produced in response to biological stress. ACTH acts to increase the production and release of cortisol via its interaction with ACTHR. Receptor activation increases the intracellular concentration of cAMP via adenylyl cyclase. Abnormal ACTH levels in the body have been linked to primary adrenal insufficiency/Addison’s disease, Cushing’s disease and secondary adrenal insufficiency